LabGenomics Co. Ltd (084650) fair value: what the stock is really worth
As of Oct 22, 2026: fair value (intrinsic value) of LabGenomics Co. Ltd stock KRW 3,361, price KRW 1,630, upside +106.2%, quality 36 out of 100. Rating: strongly undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.
How to read this chart
60‑month range 1,630 KRW – 31,400 KRW · fair‑value band 2,509 KRW – 5,017 KRW · the 1,630 KRW price screens below the 3,361 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 3, 2026.
Follow LabGenomics Co. in your weekly email
Every Wednesday you see whether LabGenomics Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
LabGenomics Co., Ltd. engages in the research and development of biotechnology products in South Korea. It is also involved in the sale of diagnostic devices. The company was founded in 2002 and is based in Seongnam-si, South Korea.
Stock analysis
LabGenomics Co. Ltd (084650) currently trades at 1,630 KRW, while our model-based Fair Value estimate is 3,361 KRW, implying the stock looks roughly 51.5% undervalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the data coverage at low.
Scenario range: 2,509 KRW (bear) to 5,017 KRW (bull), the price of 1,630 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 36/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
LabGenomics Co. Ltd reported revenue of 88.2B KRW in FY2025 versus 202B KRW in FY2021, a compound −18.8%/yr. Reported net income was −64.4B KRW in FY2025.
Key figures
Market cap 39.4B KRW (≈ $29.8M) Micro · P/S ratio 0.21 · Net margin 39.7% · Return on equity −920% · Return on assets (EBIT) 9.0% · Operating margin 53.2% · Revenue (TTM) 187B KRW · Revenue growth (YoY) −54.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 53 out of 100 (medium confidence).
What moves the price
The share trades about 87% below its 52-week high and at its 52-week low.
For context, the median of 10 Healthcare peers we cover trades at −10% fair-value upside, at 106%, 084650 screens cheaper than that median.
Fair Value models
Bear2,509 KRWFair Value 3,361 KRWBull5,017 KRW
Price 1,630 KRW · Upside +106.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.25/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+2.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−15.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−5.9%
Start year 2020 (pandemic). Over 10 years: +14.1% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.9%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
44.6% (2020) → −60.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Healthcare Providers & Services” was too small, so the broader sector is used.)Health Care · 2362 stocks
Beats the sector median on 5/9 measures
A mixed picture versus its sector peers.
Valuation
Quality Score36 · Bottom 25%
Fair Value upside+106.2% · Top 25%
Profitability
Return on assets−28.0% · Bottom 25%
Net margin (12 months)39.7% · Top 25%
Operating margin (12 months)53.2% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)−54.1% · Bottom 25%
Balance sheet
Debt / equity0.09× · Above median
Valuation Multiplesvs Health Care median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is LabGenomics Co. Ltd (084650) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of 3,361 KRW versus a price of 1,630 KRW, about +106% upside (undervalued).
What is the fair value of 084650?
Our model-based fair value for LabGenomics Co. Ltd is 3,361 KRW (as of Oct 3, 2026), built from audited fundamentals. The current price: 1,630 KRW.
What is the quality score of 084650?
LabGenomics Co. Ltd has a Quality Score of 36/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for LabGenomics Co. Ltd (084650)?
Our model-based price target is the fair value of 3,361 KRW (as of Oct 3, 2026) from 1 valuation models. Cautious scenario 2,509 KRW, optimistic scenario 5,017 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the LabGenomics Co. Ltd stock forecast for 2026?
Our models put fair value at 3,361 KRW, about +106% upside versus a price of 1,630 KRW (undervalued). Cautious scenario 2,509 KRW, optimistic scenario 5,017 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of LabGenomics Co. Ltd (084650)?
LabGenomics Co. Ltd reported trailing-twelve-month revenue of about 187B KRW (latest available figure, as of Oct 3, 2026).
What is the intrinsic value of LabGenomics Co. Ltd (084650)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For LabGenomics Co. Ltd it is 3,361 KRW per share (as of Oct 3, 2026), against a price of 1,630 KRW. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is LabGenomics Co. Ltd stock overvalued or undervalued in 2026?
As of Oct 3, 2026, 084650 trades below its calculated fair value: price 1,630 KRW, fair value 3,361 KRW, a gap of about +106% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 084650?
No. The price is what the market pays today (1,630 KRW); the fair value is what the company's own numbers justify (3,361 KRW). For LabGenomics Co. Ltd the two are 1,731 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is LabGenomics Co. Ltd worth?
The market values LabGenomics Co. Ltd at about 39.4B KRW (market capitalisation, as of Oct 3, 2026). Per share that is 1,630 KRW; our models calculate a fair value of 3,361 KRW per share.
What do the bullish and bearish scenarios say about 084650?
Our models span a range for LabGenomics Co. Ltd: cautious scenario 2,509 KRW, base 3,361 KRW, optimistic 5,017 KRW per share (as of Oct 3, 2026, price 1,630 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of LabGenomics Co. Ltd (084650)?
Balance-sheet figures for LabGenomics Co. Ltd (as of Oct 3, 2026): debt of 0.09 per unit of equity. They feed the Quality Score of 36/100, which measures business quality independently of the share price.
How far is 084650 from its 52-week high?
LabGenomics Co. Ltd trades at 1,630 KRW, about 87% below its 52-week high of 12,525 KRW and at the low of 1,630 KRW (as of Oct 22, 2026). Distance from the high says nothing about value: that is what the fair value of 3,361 KRW is for.
Which stocks are comparable to LabGenomics Co. Ltd?
From the same area (Healthcare) we also value Eli Lilly and Company, Johnson & Johnson,, AbbVie Inc, Roche Holding, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is LabGenomics Co. Ltd stock attractive at the current price?
The data as of Oct 3, 2026: price 1,630 KRW, calculated fair value 3,361 KRW (+106%), Quality Score 36/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 084650 calculated?
We run LabGenomics Co. Ltd through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 3,361 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.2 % above its aggregate fair value. LabGenomics Co. Ltd currently trades 52 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of LabGenomics Co. Ltd (084650)?
The closing price on Oct 22, 2026 was 1,630 KRW. Our model-based fair value is 3,361 KRW, about +106% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with LabGenomics Co. Ltd right now?
The large discount to fair value meets weak quality (36/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (2,509 KRW). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (2,509 KRW to 5,017 KRW) leaves room in how you read the outcome.
Key figures of LabGenomics Co. Ltd
How large is the market capitalisation of LabGenomics Co. Ltd (084650)?
The market capitalisation of LabGenomics Co. Ltd is 39.4B KRW (≈ $29.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of LabGenomics Co. Ltd (084650)?
The price-to-sales ratio of LabGenomics Co. Ltd is 0.21 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of LabGenomics Co. Ltd (084650)?
The net margin of LabGenomics Co. Ltd is 39.7% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of LabGenomics Co. Ltd (084650)?
The return on equity (ROE) of LabGenomics Co. Ltd is −920% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of LabGenomics Co. Ltd (084650)?
On an EBIT basis the return on assets of LabGenomics Co. Ltd is 9.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of LabGenomics Co. Ltd (084650)?
The operating margin of LabGenomics Co. Ltd is 53.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at LabGenomics Co. Ltd (084650)?
Revenue at LabGenomics Co. Ltd is growing −54.1% versus a year earlier (3y avg −15.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at LabGenomics Co. Ltd (084650)?
Earnings per share at LabGenomics Co. Ltd are growing −68.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does LabGenomics Co. Ltd (084650) generate?
The free cash flow of LabGenomics Co. Ltd is −32.2B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does LabGenomics Co. Ltd (084650) carry?
The net debt of LabGenomics Co. Ltd is 41.9B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch LabGenomics Co. Ltd in the live analysis
One click puts LabGenomics Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Thin data
Oct 3, 2026